• Trifluoperazine 2HCl: Assay Design Beyond D2

  2026-08-19

  Trifluoperazine 2HCl is a potent dopamine D2 receptor inhibitor for dissecting receptor signaling while designing orthogonal ROS and autophagy assays. This guide translates phenothiazine macrophage findings into practical, evidence-aware workflows without confusing class effects with compound-specific conclusions.

• Thymoquinone Protects Against Doxorubicin Cardiotoxicity

  2026-08-19

  A 2025 mouse study reports that thymoquinone reduces doxorubicin-induced cardiac injury, with evidence linking protection to Nrf2/HO-1 activation, improved antioxidant capacity, and reduced ferroptosis-associated damage. The work provides a useful preclinical framework for connecting cardiac function, redox biomarkers, mitochondrial ultrastructure, and iron-dependent cell death in chemotherapy toxicity research.

• NSAID Cytotoxicity in Canine Osteosarcoma Cells

  2026-08-18

  This 2005 in vitro study compared deracoxib and piroxicam in three canine osteosarcoma cell lines and a fibroblast line. Deracoxib produced broader and more selective viability loss than piroxicam, but neither drug showed DNA-fragmentation evidence of apoptosis, emphasizing the importance of concentration, cell-line selection, and endpoint choice in translational cancer research.

• Angiotensin Peptides and SARS-CoV-2 Receptor Binding

  2026-08-18

  The reference study identifies a previously underappreciated effect of naturally occurring angiotensin peptides: selective enhancement of SARS-CoV-2 spike protein binding to host receptors, especially AXL. Its peptide-truncation and tyrosine-modification experiments provide a structure–activity framework for interpreting how renin–angiotensin system metabolites may influence viral receptor interactions, while also highlighting the need for infection and in vivo validation.

• IDH1-R132H Autopalmitoylation in Cancer Cells

  2026-08-17

  A recent Nature Chemical Biology study identifies C269 autopalmitoylation as a mutation-associated regulatory mechanism that enhances IDH1-R132H activity. The work links fatty acid metabolism with oncometabolite production, epigenetic remodeling, and transformation, while highlighting a hydrophobic pocket as a potential therapeutic vulnerability.

• Trifluoperazine 2HCl: Assay Design

  2026-08-17

  Trifluoperazine 2HCl is a nanomolar dopamine D2 receptor inhibitor for rigorous studies of receptor signaling, autophagy, and ROS biology. This assay-centered guide explains how to separate target engagement from downstream cellular effects and translate phenothiazine research into reproducible experimental decisions.

• NF449 and Selective Platelet P2X1 Blockade

  2026-08-16

  The reference study established NF449 as a concentration-dependent antagonist of platelet purinergic receptors, with substantially greater activity at P2X1 than at P2Y1 or P2Y12 under the tested conditions. By combining human platelet assays with mouse thrombosis models, it connected P2X1 blockade to reduced platelet activation and thrombus formation while examining whether hemostatic bleeding was preserved.

• Propranolol: Mechanism, Evidence, and Research Use

  2026-08-15

  Propranolol is a non-selective β-adrenergic receptor blocker used to study cardiovascular regulation, essential tremor therapy, and emotional memory modulation. Its β1 and β2 receptor antagonism is well established, while CNS, metabolic, and anti-inflammatory findings require indication-specific interpretation and controlled experimental design.

• Entinostat: HDAC Biology from Cancer to Regeneration

  2026-08-14

  Entinostat (MS-275) is more than a selective class I HDAC inhibitor: its effects reveal how timing, tissue context, and target engagement shape epigenetic experiments. This guide connects cancer cell proliferation inhibition with mechanistic lessons from axolotl limb regeneration research.

• AS1842856: A Precision Foxo1 Tool for Translation

  2026-08-14

  AS1842856 offers translational researchers a direct way to perturb Foxo1 activity while preserving Foxo1 abundance. This thought-leadership analysis connects hepatic gluconeogenesis and autophagy research with the PI3K-Akt-Foxo1 signaling framework implicated in mesenchymal stem cell activation, while defining the evidence boundaries for responsible experimental translation.

• 4-MUG: Translating Lysosomal Enzyme Recovery

  2026-08-13

  4-Methylumbelliferyl-β-D-Glucopyranoside (4-MUG) turns lysosomal glucosidase activity into a quantitative fluorescent signal, helping translational teams connect optimized GBA1 mRNA expression with functional enzyme recovery in Gaucher disease models.

• PD98059 for Branch-Resolved MAPK Assays

  2026-08-13

  PD98059 is a MEK inhibitor for dissecting ERK1/2-dependent cell-cycle control, apoptosis induction in leukemia cells, and neuroprotection in ischemia models. This guide focuses on experimental interpretation, branch-specific controls, and assay design rather than repeating a standard product overview.

• Chronic Stress, Mitochondria, and Depression-Like Behavior

  2026-08-12

  A February 2025 study used chronic unpredictable mild stress (CUMS) in rats to connect depression-like behavior with mitochondrial dysfunction and inflammatory signaling in the hippocampus and prefrontal cortex. Its key advance was a mitochondrial-targeted antioxidant intervention: intracerebroventricular MnTBAP reduced stress-associated behavioral abnormalities, supporting mitochondrial dysfunction as a modifiable contributor rather than merely a correlated feature.

• Selective Nanomolar IRAP Inhibitors from Bestatin

  2026-08-12

  The reference study develops a stereoselective route to α-hydroxy-β-amino acid derivatives of bestatin and identifies a cell-active, low-nanomolar inhibitor of insulin-regulated aminopeptidase (IRAP) with more than 120-fold selectivity over related enzymes. Biochemical testing and X-ray crystallography show that interactions with the IRAP GAMEN loop are an important, previously underappreciated determinant of potency and selectivity.

• Letrozole Workflows for Breast Cancer Research

  2026-08-11

  Build reproducible aromatase-inhibition assays with Letrozole, from DMSO stock preparation through estrogen, ERα, and proliferation readouts. The workflow also shows how to distinguish estrogen-biosynthesis blockade from receptor-directed endocrine effects and how to troubleshoot model-specific variability.

11425 records 1/762 page Next 12345 下5页 Last page